DIVERSE VOICES STRENGTHEN BRAND CHARACTER

| August 14, 2019

article image
What character appears in the most films and television programs? Dracula? God? Santa Claus?  All of those make the top ten list, but none is the correct answer. Satan (or The Devil) is a character is more than 840 projects – more than any other character. If you limit the list to mortals, the Guinness Book of World Records recognizes fictional detective Sherlock Holmes as the most portrayed human. More than 75 actors have taken on the role, including Sir Christopher Lee, John Cleese, Charlton Heston, Roger Moore, Robert Downey Jr, Will Farrell, Benedict Cumberbatch, and Yuko Takeuchi (who plays a female version of the character in a new series from HBO Asia and Hulu Japan). The diversity of these distinct voices and performances makes the Sherlock Holmes brand richer and stronger. In fact, it highlights the importance of understanding the difference between voice and character.
Become a contributor

Spotlight

Alnylam Pharmaceuticals

We are developing an innovative, entirely new class of medicines called “RNAi therapeutics” to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNA interference (RNAi), and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn’t have to wait for hope.

Spotlight

Alnylam Pharmaceuticals

We are developing an innovative, entirely new class of medicines called “RNAi therapeutics” to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNA interference (RNAi), and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn’t have to wait for hope.

RELATED ARTICLES